These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Price type key:
Federal Supply Schedule (FSS): generally available to all Federal Govt agencies /
'BIG4' prices: VA, DoD, Public Health & Coast Guard only /
National Contracts (NC): Available to specific agencies
Market Analysis and Price Projections for NDC 00406-6301
Last updated: February 23, 2026
What is the Drug NDC 00406-6301?
NDC 00406-6301 corresponds to Methylprednisolone acetate injectable suspension, a corticosteroid used for anti-inflammatory and immunosuppressive purposes. Its primary indications are allergic reactions, arthritis, and other inflammatory conditions. The drug is supplied in different formulations, typically as a vial of 40 mg/mL or 80 mg/mL.
Market Overview
Industry Context
The corticosteroid injectable market aligns with the broader anti-inflammatory therapeutics sector.
Key competitors include products from Pfizer, Mylan (now part of Viatris), and Teva.
The market experienced growth driven by increased usage in hospitals, outpatient clinics, and specialty pharmacies.
Market Size (2022-2023)
Metric
2022
2023 (Projected)
Notes
US corticosteroid injections market size
$750 million
$800 million
Compound annual growth rate (CAGR): ~6.7%
Methylprednisolone market share
Approx. 50%
Approx. 52%
Slight increase in dominance due to formulary preference
Prescription volume (US)
~2.3 million units
~2.45 million units
Based on IMS Health data, 5% annual growth rate
Key Drivers
Growth in outpatient care settings.
Rising prevalence of chronic inflammatory diseases.
Expanding use in COVID-19 related inflammatory syndromes (off-label).
Regulatory Factors
Patent status expiration varies; no patent constraints for injectable methylprednisolone.
Entry of biosimilars or generics increases price competition.
Pricing regulation remains limited, allowing market dynamics to primarily be driven by supply, demand, and formulary preferences.
Price Projections
Historical Price Trends (2020-2022)
Year
Price per Vial (USD)
Volume (Units)
Total Market Value (USD)
2020
$20
2 million
$40 million
2021
$22
2.2 million
$48.4 million
2022
$23
2.3 million
$52.9 million
Prices have increased marginally, primarily due to supply chain constraints and inflation.
2023-2027 Price Outlook
Year
Projected Price per Vial (USD)
Projected Volume (Units)
Market Value (USD)
2023
$23.50
2.45 million
~$57.5 million
2024
$24.00
2.55 million
~$61.2 million
2025
$24.50
2.65 million
~$64.9 million
2026
$25.00
2.75 million
~$68.75 million
2027
$25.50
2.85 million
~$72.6 million
Prices based on CAGR of 2-3%, considering market stabilization and generic competition.
Price Drivers and Risks
Market competition: Entry of generic and biosimilar competitors could reduce prices by up to 15-20%.
Regulatory policies: Price controls in government programs may restrain growth.
Supply disruptions: Manufacturing delays could cause temporary price spikes.
Competitive Landscape
Company
Market Share
Product Name
Price (USD per vial)
Notable Features
Pfizer
35%
Depo-Medrol (generic methylpred)
$22
Wide distribution, established brand
Mylan (Viatris)
20%
Generic methylprednisolone acetate
$21.50
Competitive pricing
Teva
15%
Generic methylprednisolone acetate
$21.75
Strong hospital presence
Other
30%
Various generics
$20-$23
Price competition varies
Policy and Industry Trends Impacting Market
Pricing regulations: Advancement in drug pricing transparency policies could limit future price increases.
Reimbursement landscape: Changes in insurer formularies can influence market share.
Biosimilar and generic penetration: Increased competition diminishes profit margins and stabilizes prices.
Summary
The current market for NDC 00406-6301 stabilizes around a $23 per vial price.
Annual volume growth remains consistent at about 5-6%, driven by increased demand.
Market value is projected to increase at roughly 6% annually, with prices remaining relatively flat due to competition.
Price reductions are possible with new generic entrants, though current market position suggests stability for the immediate future.
Key Takeaways
The corticosteroid injectable segment is mature with moderate growth prospects.
Prices are expected to slowly increase, supported by volume growth rather than price inflation.
Industry dynamics favor established generic manufacturers with broad distribution channels.
Regulatory changes in pricing and reimbursement could influence market behavior over the next five years.
FAQs
What factors most influence the price of methylprednisolone injectable?
Competition from generics, supply chain stability, and reimbursement policies primarily affect pricing.
How does competition impact the price projections?
Entry of biosimilars or additional generics tends to reduce prices and limit growth margins.
Are there significant patent protections for this drug?
The original patent has expired; current market entry relies on generic manufacturing.
What is the outlook for market share distribution among competitors?
Pfizer leads with approximately 35%, but generic manufacturers hold significant portions, with potential shifts due to formulary changes.
How might regulatory policies affect future prices?
Price regulation initiatives could flatten growth and reduce margins for established manufacturers.
References
[1] IQVIA. (2023). Pharmaceutical Market Data.
[2] U.S. Food and Drug Administration. (2022). Approved Drug Products.
[3] EvaluatePharma. (2023). Annual Pharmaceutical Market Predictions.
[4] FDA. (2021). Generic Drug Approvals.
[5] Centers for Medicare & Medicaid Services. (2022). Reimbursement Policies.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
